BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
화요일, 9월 22

Atara Biotherapeutics Inc

ATRANASDAQ
Trade with Public
Trade with Public
$9.38
-0.31-3.2%
가까이에: Sep 18, 5:00 PM EST
$9.69
N/A
프리마켓: 7:00 AM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교주식 보고서

Atara Biotherapeutics Financials

Atara Biotherapeutics (ATRA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Atara Biotherapeutics Q2 EPS $(0.32), Inline, Sales $630.000K Beat $366.667K Estimate

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.32) per share which met the analyst consensus estimate. This is a 268.42 percent decrease over earnings of $0.19 per share from the same period last
Benzinga Newsdesk

PRO
Atara Biotherapeutics Q1 EPS $(0.29) Beats $(0.41) Estimate, Sales $516.000K Miss $2.850M Estimate

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.41) by 27.5 percent. This is a 108.29 percent decrease over earnings of $3.50 per share
Benzinga Newsdesk

PRO
Atara Biotherapeutics Q4 EPS $(0.25) Beats $(0.44) Estimate, Sales $1.595M Miss $2.671M Estimate

Benzinga Newsdesk

PRO
Atara Biotherapeutics Q3 EPS $(0.32) Beats $(0.86) Estimate, Sales $3.453M Beat $1.398M Estimate

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.86) by 62.79 percent. This is a 89.08 percent increase over losses of $(2.93) per share
Benzinga Newsdesk

PRO
Atara Biotherapeutics Q2 EPS $0.19 Beats $(0.81) Estimate, Sales $17.57M Beat $5.67M Estimate

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $(0.81) by 123.54 percent. This is a 106.13 percent increase over losses of $(3.10) per
Benzinga Newsdesk

PRO
Atara Biotherapeutics Q1 EPS $3.50 Beats $(1.98) Estimate, Sales $98.15M Beat $5.67M Estimate

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly earnings of $3.50 per share which beat the analyst consensus estimate of $(1.98) by 276.77 percent. This is a 160.87 percent increase over losses of $(5.75) per
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved